Nature Communications (Feb 2020)
Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes
- Kensuke Matsumura,
- Kaoru Seiriki,
- Shota Okada,
- Masashi Nagase,
- Shinya Ayabe,
- Ikuko Yamada,
- Tamio Furuse,
- Hirotoshi Shibuya,
- Yuka Yasuda,
- Hidenaga Yamamori,
- Michiko Fujimoto,
- Kazuki Nagayasu,
- Kana Yamamoto,
- Kohei Kitagawa,
- Hiroki Miura,
- Nanaka Gotoda-Nishimura,
- Hisato Igarashi,
- Misuzu Hayashida,
- Masayuki Baba,
- Momoka Kondo,
- Shigeru Hasebe,
- Kosei Ueshima,
- Atsushi Kasai,
- Yukio Ago,
- Atsuko Hayata-Takano,
- Norihito Shintani,
- Tokuichi Iguchi,
- Makoto Sato,
- Shun Yamaguchi,
- Masaru Tamura,
- Shigeharu Wakana,
- Atsushi Yoshiki,
- Ayako M. Watabe,
- Hideyuki Okano,
- Kazuhiro Takuma,
- Ryota Hashimoto,
- Hitoshi Hashimoto,
- Takanobu Nakazawa
Affiliations
- Kensuke Matsumura
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Kaoru Seiriki
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Shota Okada
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Masashi Nagase
- Institute of Clinical Medicine and Research, Jikei University School of Medicine
- Shinya Ayabe
- Experimental Animal Division, RIKEN BioResource Research Center
- Ikuko Yamada
- Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center
- Tamio Furuse
- Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center
- Hirotoshi Shibuya
- Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center
- Yuka Yasuda
- Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
- Hidenaga Yamamori
- Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
- Michiko Fujimoto
- Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
- Kazuki Nagayasu
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Kana Yamamoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Kohei Kitagawa
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Hiroki Miura
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Nanaka Gotoda-Nishimura
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Hisato Igarashi
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Misuzu Hayashida
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Masayuki Baba
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Momoka Kondo
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Shigeru Hasebe
- Department of Pharmacology, Graduate School of Dentistry, Osaka University
- Kosei Ueshima
- Department of Pharmacology, Graduate School of Dentistry, Osaka University
- Atsushi Kasai
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Yukio Ago
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Atsuko Hayata-Takano
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Norihito Shintani
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Tokuichi Iguchi
- Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University
- Makoto Sato
- Department of Anatomy and Neuroscience, Graduate School of Medicine, Osaka University
- Shun Yamaguchi
- Department of Morphological Neuroscience, Gifu University Graduate School of Medicine
- Masaru Tamura
- Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center
- Shigeharu Wakana
- Technology and Developmental Team for Mouse Phenotype Analysis, RIKEN BioResource Research Center
- Atsushi Yoshiki
- Experimental Animal Division, RIKEN BioResource Research Center
- Ayako M. Watabe
- Institute of Clinical Medicine and Research, Jikei University School of Medicine
- Hideyuki Okano
- Department of Physiology, Keio University School of Medicine
- Kazuhiro Takuma
- Department of Pharmacology, Graduate School of Dentistry, Osaka University
- Ryota Hashimoto
- Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry
- Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- Takanobu Nakazawa
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University
- DOI
- https://doi.org/10.1038/s41467-020-14697-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
De novo mutations significantly contribute to autism spectrum disorders (ASD). Here, the authors demonstrate that ASD-associated de novo mutations in the POGZ gene, one of a high-confidence ASD gene, lead to ASD-related impaired neuronal development and disrupted mature cortical network function.